Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1528853
This article is part of the Research Topic Cancer Biomarkers: Molecular Insights into Diagnosis, Prognosis, and Risk Prediction View all 10 articles

Identification of DAP3 as candidate prognosis marker and potential therapeutic target for hepatocellular carcinoma

Provisionally accepted
Liu-Xia Yuan Liu-Xia Yuan Zhi-qiang Yue Zhi-qiang Yue *Qin-Rong Ma Qin-Rong Ma *Peng Zhang Peng Zhang Feng Xiao Feng Xiao Lin Chen Lin Chen *
  • Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, jiangsu, 226000, China

The final, formatted version of the article will be published soon.

    Background: Among malignant tumors, hepatocellular carcinoma (HCC) is both prevalent and highly lethal. Most patients with advanced-stage liver cancer have a poor prognosis. Death-associated protein 3 (DAP3) is reportedly related to tumors and may hold great promise for the future.Methods: DAP3 transcriptome data along with related clinical information were obtained from The Cancer Genome Atlas (TCGA), GEO, and ICGC databases. We assessed its prognostic value, clinical relevance, associated pathways, immune infiltration, gene mutations, and sensitivity to chemotherapeutics. A prognostic risk model was subsequently developed and evaluated using receiver operating characteristic (ROC) curves and Kaplan-Meier (KM) plots. Additionally, a nomogram was created and validated through calibration and decision curve analysis (DCA). Furthermore, quantitative real-time PCR (qRT-PCR), Western blot, and immunohistochemical (IHC) staining were performed to examine the expression of DAP3 in HCC. Finally, gene knockdown and overexpression experiments, along with cell counting kit-8 (CCK-8) assays, colony formation assays, and tests for cell apoptosis, migration, and invasion, were conducted to investigate the role of DAP3 in HCC.The study discovered that DAP3 expression was linked to HCC subtypes, and its high expression was linked to a poor prognosis. There were significant differences in immune infiltration level, mutation level, prognostic value and chemotherapeutic efficacy. Subsequently, we constructed a prognostic model and demonstrated that high risk score was significantly related to a poor survival rate. A predictive nomogram demonstrated that the nomogram model was effective prediction tool that can accurately predict the survival rate of patients with different clinical characteristics.Additionally, DAP3 expression significantly increased in both tissue samples and cell lines. Elevated levels of DAP3 were correlated with larger tumor size and higher alphafetoprotein (AFP) levels, and Cox analysis confirmed that DAP3 was a clinically independent prognostic marker. Finally, cell assays revealed that the knockdown of DAP3 significantly impeded cell proliferation and metabolic activity and induced apoptosis. Conversely, the overexpression of DAP3 had opposite effects on these cellular processes.Conclusions: Our study on DAP3 can provide a reference for HCC diagnosis, treatment and prognosis assessment.

    Keywords: Hepatocellular Carcinoma, DAP3, Prognostic model, bioinformatics, biomarker

    Received: 15 Nov 2024; Accepted: 03 Feb 2025.

    Copyright: © 2025 Yuan, Yue, Ma, Zhang, Xiao and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zhi-qiang Yue, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, jiangsu, 226000, China
    Qin-Rong Ma, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, jiangsu, 226000, China
    Lin Chen, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, jiangsu, 226000, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.